Cresset Asset Management
RXRX icon

Cresset Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Cresset Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$143K Hold
38,852
– – ﹤0.01% 1632
2026
Q1 		$119K Sell
38,852
-385
-1% -$1.49K ﹤0.01% 1524
2025
Q4 		$160K Sell
39,237
-51
-0.1% -$253 ﹤0.01% 1527
2025
Q3 		$192K Buy
39,288
+15,125
+63% +$79.4K ﹤0.01% 1435
2025
Q2 		$122K Sell
24,163
-714
-3% -$3.51K ﹤0.01% 1351
2025
Q1 		$132K Sell
24,877
-152
-0.6% -$1.11K ﹤0.01% 1590
2024
Q4 		$169K Sell
25,029
-45,663
-65% -$307K ﹤0.01% 1587
2024
Q3 		$466K Sell
70,692
-2,660
-4% -$19.1K ﹤0.01% 1556
2024
Q2 		$550K Buy
73,352
+9,791
+15% +$85.4K ﹤0.01% 1394
2024
Q1 		$634K Buy
63,561
+11,392
+22% +$127K ﹤0.01% 1217
2023
Q4 		$514K Buy
52,169
+37,092
+246% +$264K ﹤0.01% 1222
2023
Q3 		$115K Buy
+15,077
New +$150K ﹤0.01% 1699
2023
Q1 		– Sell
-46,861
Closed -$361K – 857
2022
Q4 		$361K Hold
46,861
– – ﹤0.01% 492
2022
Q3 		$499K Hold
46,861
– – 0.01% 512
2022
Q2 		$381K Sell
46,861
-156
-0.3% -$1.04K ﹤0.01% 640
2022
Q1 		$337K Sell
47,017
-86,420
-65% -$918K ﹤0.01% 732
2021
Q4 		$2.29M Buy
+133,437
New +$2.51M 0.02% 271

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Cresset Asset Management's RXRX Position: Q2 2026 in Review

Cresset Asset Management held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 38,852 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #1632.

Cresset Asset Management first reported a position in RXRX in Q4 2021 and has held it in 17 quarters since. The position peaked at $2.29M in Q4 2021. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Cresset Asset Management held 38,852 shares of Recursion Pharmaceuticals worth $143K as of Q2 2026.
  • Cresset Asset Management left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1632 holding.
  • Cresset Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 17 quarters since.
  • Cresset Asset Management's Recursion Pharmaceuticals position peaked at $2.29M in Q4 2021.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.